TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02792348

Intervention type: OTHER
Intervention: Laboratory biomarker analysis on urine sample
Description: Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance

Intervention type: OTHER
Intervention: Laboratory biomarker analysis on urine sample
Description: Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
Study: NCT00688428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg/ASA 325mg
Description: combination capsule, administered as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg capsule, administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 325mg tablet, administered as a single oral dose
Study: NCT04788446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-flipped Game-based Learning
Description: The intervention was 8 weeks, forty minutes adjusted Mediterranean diet learning plan once a week, which includes the 20 minutes for the Mediterranean food table game, and the 20 minutes for the Mediterranean diet nutrition course. The topic of the course includes the relationship between Mediterranean diet and dementia, knowledge of Mediterranean diet, how to integrate local food ingredients into the Mediterranean diet, etc.
Study: NCT04577625

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri (L. reuteri)
Description: L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
Study: NCT04788446

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Balanced diet
Description: Given a balanced diet nutrition health education manual for the aged.
Study: NCT03588052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VISTA using PRF
Description: Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VISTA using SCTG
Description: Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured
Study: NCT02651142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients receive SLNB
Description: Patients receive sentinel lymph node biopsy
Study: NCT02916836

Intervention type: OTHER
Intervention: therapeutic drug conciliation sheet (TDC)
Description: Use of therapeutic drug conciliation sheet (TDC)

Intervention type: OTHER
Intervention: No Use of therapeutic drug conciliation sheet (TDC)
Study: NCT00031512

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pleconaril
Description: 5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
Study: NCT02500654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain®
Description: Surgery and Emdogain®

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery alone
Description: Surgery alone
Study: NCT02967588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients.
Study: NCT03884244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: The group who take chewing gum after operation
Study: NCT02297880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing low calorie sweeteners
Description: Beverage containing low calorie sweeteners

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Still water
Description: Still water (no flavour)
Study: NCT00754936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20 mg by mouth daily
Study: NCT04696341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Matrix Rhythm Therapy
Description: Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
Study: NCT00384293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: niacin (+) laropiprant (MK0524A)
Description: niacin (+) laropiprant (2 g) po qd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: niacin (+) laropiprant (2 g) placebo po qd.
Study: NCT01862419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alert
Study: NCT05369091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 10mg
Description: Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
Study: NCT02406638

Intervention type: OTHER
Intervention: 3D pelvic floor ultrasound
Description: Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life

Intervention type: OTHER
Intervention: 3D pelvic floor ultrasound
Description: Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life

Intervention type: OTHER
Intervention: 3D pelvic floor ultrasound
Description: Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
Study: NCT00007761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual (psychiatric) Care
Study: NCT02725424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
Study: NCT00519922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesthesia, Balance, and Agility (KBA) Exercise
Description: Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion \& agility, dynamic proprioception,functional strength \& endurance.~Kinesthesia \& Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability \& confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia \& balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard LE Strength Training
Description: Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal \& external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
Study: NCT01419899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Description: A 20-30 minute motivational based discussion
Study: NCT01758341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation
Description: Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Description: ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HabibTM EndoHPB catheter
Description: Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)
Study: NCT01502124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
Study: NCT01803269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclodextrin-based polymer-camptothecin CRLX101
Description: Given IV
Study: NCT03223909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-087
Description: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Preservative Free
Description: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
Study: NCT03879096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise and Education
Description: Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
Study: NCT01529931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair2Go
Description: Hair2Go treatment once a month for 6 months
Study: NCT01344616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle support
Description: computer-based lifestyle improvement support and clinician support
Study: NCT04886557

Intervention type: PROCEDURE
Intervention: L4-L5 decompression and dynamic instrumentation
Description: All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (\< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
Study: NCT01974882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
Study: NCT02292121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a solution of mannitol and lactitol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a solution of mannitol and lactitol
Study: NCT01033760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine
Description: raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir; ritonavir; emtricitabine/tenofovir
Description: darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
Study: NCT02853864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.0 ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.0 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4 ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.4 ng/ml
Study: NCT01056835

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: prostaglandin I2 analogue
Study: NCT02026258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezotome-Corticision
Description: Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontics
Description: Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontics
Description: Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
Study: NCT03321344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound Thermal ablation
Description: Focused Ultrasound Thermal ablation of the Medial Nerve Branch
Study: NCT02009735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virosensor
Description: virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens.
Study: NCT00746330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MFF)
Description: Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
Study: NCT02853864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6 ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.6 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8 ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.8 ng/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness